Healthcare provider profile · identity verified

David Tanaka, MD

Internal Medicine · DENVER, CO · NPI 1386722643

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	389	130
Omeprazole	Omeprazole	181	62
Lisinopril	Lisinopril	161	58
Amlodipine Besylate	Amlodipine Besylate	153	62
Levothyroxine Sodium	Levothyroxine Sodium	142	54
Rosuvastatin Calcium	Rosuvastatin Calcium	134	48
Tamsulosin Hcl	Tamsulosin Hcl	110	38
Zolpidem Tartrate	Zolpidem Tartrate	109	39
Losartan Potassium	Losartan Potassium	108	43
Metoprolol Succinate	Metoprolol Succinate	76	32
Hydrochlorothiazide	Hydrochlorothiazide	68	24
Trazodone Hcl	Trazodone Hcl	59	24
Eliquis	Apixaban	58	15
Metformin Hcl	Metformin Hcl	58	24
Simvastatin	Simvastatin	55	16
Gabapentin	Gabapentin	54	18
Oxycodone Hcl	Oxycodone Hcl	54	21
Fluticasone Propionate	Fluticasone Propionate	50	20
Famotidine	Famotidine	49	18
Ozempic	Semaglutide	46	15
Pantoprazole Sodium	Pantoprazole Sodium	44	16
Allopurinol	Allopurinol	43	14
Lorazepam	Lorazepam	43	14
Sertraline Hcl	Sertraline Hcl	42	11
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	39	suppressed
Jardiance	Empagliflozin	38	13
Metformin Hcl Er	Metformin Hcl	38	14
Metoprolol Tartrate	Metoprolol Tartrate	37	18
Citalopram Hbr	Citalopram Hydrobromide	36	12
Albuterol Sulfate Hfa	Albuterol Sulfate	34	21
Chlorthalidone	Chlorthalidone	34	12
Finasteride	Finasteride	34	13
Xarelto	Rivaroxaban	33	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	30	12
Oxycontin	Oxycodone Hcl	30	suppressed
Estradiol	Estradiol	29	13
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	26	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	12
Fluoxetine Hcl	Fluoxetine Hcl	26	suppressed
Mirtazapine	Mirtazapine	26	suppressed
Alendronate Sodium	Alendronate Sodium	25	12
Bupropion Xl	Bupropion Hcl	25	suppressed
Meloxicam	Meloxicam	25	13
Pregabalin	Pregabalin	25	14
Triamcinolone Acetonide	Triamcinolone Acetonide	25	14
Duloxetine Hcl	Duloxetine Hcl	24	11
Symbicort	Budesonide/Formoterol Fumarate	23	suppressed
Methadone Hcl	Methadone Hcl	22	suppressed
Furosemide	Furosemide	21	11
Ezetimibe	Ezetimibe	19	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Atenolol	Atenolol	18	suppressed
Montelukast Sodium	Montelukast Sodium	17	suppressed
Spironolactone	Spironolactone	16	suppressed
Donepezil Hcl	Donepezil Hcl	15	suppressed
Tramadol Hcl	Tramadol Hcl	15	suppressed
Carvedilol	Carvedilol	14	suppressed
Enalapril Maleate	Enalapril Maleate	14	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	14	suppressed
Potassium Chloride	Potassium Chloride	14	suppressed
Prednisone	Prednisone	14	11
Risedronate Sodium	Risedronate Sodium	14	suppressed
Synthroid	Levothyroxine Sodium	14	suppressed
Warfarin Sodium	Warfarin Sodium	14	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Atrovent Hfa	Ipratropium Bromide	12	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Glipizide	Glipizide	12	suppressed
Ibuprofen	Ibuprofen	12	suppressed
Ipratropium Bromide	Ipratropium Bromide	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Clindamycin Phosphate	Clindamycin Phosphate	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Dantrolene Sodium	Dantrolene Sodium	11	suppressed
Diclofenac Sodium	Diclofenac Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error